Stellest 2.0 Lenses
Essilor’s most efficacious myopia management lenses
In 2020, Essilor® unveiled the first generation of Essilor® Stellest® lenses, slowing myopia progression by 67% on average8 9, helping millions of children worldwide.
Building on the success of the previous generation, Essilor® Stellest® 2.0 lenses provide higher power, higher effiacy in managing myopia progression vs Essilor® Stellest® lenses (first generation).
Did you know?
By 2050, half the world’s population
could be myopic
Myopia, often caused by an increase in eye length17 is a lifelong condition and its progression could affect children’s long-term visual health18 19. By 2050, half the world’s population could be myopic20.
The younger a child becomes myopic, the faster their myopia may progress21. Slowing myopia progression is key for a child’s future visual health. Each diopter counts, start as early as possible.
Essilor’s most efficacious myopia management lenses
Manage myopia progression via H.A.L.T.12
MAX technology
With Essilor® Stellest® 2.0 lenses, eye growth in myopic children was 1.88 times slower than with the first generation of Essilor® Stellest® lenses13 14. The enhanced efficacy of Essilor® Stellest® 2.0 lenses is supported by clinical trial results15.
- Correct myopia – designed to provide sharp vision with your child’s prescription
- Myopia management – slow myopic eye growth with H.A.L.T. MAX technology
Why choose the Essilor Stellest 2.0 lenses for your kid?
Can I equip my child with Essilor Stellest 2.0 lenses?
Our clinical results show that Essilor® Stellest® 2.0 lenses are our most efficacious solution for managing myopia in children, including younger ones who may be at higher risk of progression16.
ASK OUR TEAM ABOUT STELLEST 2.0 LENSES
Legal disclaimers
1. Compared to products within the Essilor® portfolio
2. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
3. Higher power refers to the increased depth of volume of non-focused light in front of the retina—twice that of Essilor® Stellest® lenses by design—and is not associated with a doubling of lens power, lenslet power, or efficacy.
4. Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children.
5. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
6. No significant difference in distance BCVA between Essilor® Stellest® and Essilor® Stellest® 2.0 lenses when looking through the central zone of the lens (Drobe B, et al. Effect of increased power and asphericity of lenslets in myopia control spectacle lenses on short-term visual performance. Invest Ophthalmol Vis Sci. 2025;66:2144)
7. When looking through the peripheral aspherical lenslet portion of the lens, there was no significant difference between Essilor® Stellest® and Essilor® Stellest® 2.0 lenses in high contrast distance visual acuity (VA), low contrast distance VA and low contrast near VA (EssilorLuxottica. Data on File. 2025 Effect of increased power and asphericity of lenslets in myopia control spectacle lenses on short-term visual performance.)
8. Compared to single vision lenses, when worn 12 hours per day every day for two consecutive years.
9. Bao J, et al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA ophthalmology. 2022;140(5):472-8;
10. Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children.
11. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
12. H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.
13. Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 myopic children. The estimated cumulative 12-month axial length change (eye growth) was 0.228 mm with Essilor® Stellest® lenses and 0.121 mm with Essilor® Stellest® 2.0 lenses. The 1.88× ratio reflects the relative difference between these values (1 / [0.121 / 0.228] = 1.88).
14. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
15. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
16. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
17. Flitcroft DI, et al. IMI–defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Investigative ophthalmology & visual science. 2019 Feb 28;60(3):M20-30.
18. Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optometry and Vision Science. 2019 Jun 1;96(6):463-5.
19. Sankaridurg P, at al. IMI impact of myopia. Investigative ophthalmology & visual science. 2021;62(5):2.
20. Holden BA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123:1036–42.
21. Sankaridurg P. A less myopic future: what are the prospects?. Clinical and Experimental Optometry. 2015;98(6):494-6.
*Essilor® Stellest® 2.0 lenses are not currently available in all countries, including the U.S. and have not been cleared by the U.S. FDA.